Literature DB >> 3050294

Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation.

M Buschle1, J W Janssen, H Drexler, J Lyons, B Anger, C R Bartram.   

Abstract

Three cases of idiopathic myelofibrosis were screened for the presence of mutations at codon 12, 13, or 61 of the ras gene family by a rapid method based on polymerase chain reaction and hybridization to mutation-specific oligonucleotides. PB cells of one patient showed a point mutation at codon 12 of the N-ras oncogene. This molecular genetic hallmark was used to investigate the clonal relationship of different cell lineages by cell separation analysis. Presence of the N-ras 12 mutation in granulocytes, monocytes, B cells, and T lymphocytes, as well as erythroblasts, indicates that idiopathic myelofibrosis originates from a pluripotent stem cell, at least in this patient.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3050294

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

Review 1.  Pathogenesis of idiopathic myelofibrosis: role of growth factors.

Authors:  J T Reilly
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

Review 2.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 3.  The therapy of myelofibrosis: targeting pathogenesis.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 4.  Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia.

Authors:  M C Le Bousse-Kerdilès; M C Martyré
Journal:  Springer Semin Immunopathol       Date:  1999

5.  Circulating CD34+ cells of primary myelofibrosis patients contribute to myeloid-dominant hematopoiesis and bone marrow fibrosis in immunodeficient mice.

Authors:  Noriyuki Saito; Takuji Yamauchi; Noriaki Kawano; Rintaro Ono; Shuro Yoshida; Toshihiro Miyamoto; Tomohiko Kamimura; Leonard D Shultz; Yoriko Saito; Katsuto Takenaka; Kazuya Shimoda; Mine Harada; Koichi Akashi; Fumihiko Ishikawa
Journal:  Int J Hematol       Date:  2021-11-13       Impact factor: 2.490

6.  Thalidomide treatment in a myelofibrosis patient with leukemia transformation.

Authors:  Wei-Han Huang; Ming-Shing Li; Sung-Chao Chu; Tso-Fu Wang; Ruey-Ho Kao; Yi-Feng Wu
Journal:  Int J Hematol       Date:  2013-12-04       Impact factor: 2.490

7.  Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis.

Authors:  Marko Lucijanic; Zdravko Mitrovic; David Cicic; Zeljko Prka; Vlatko Pejsa; Ana Livun; Tajana Stoos-Veic; Zeljko Romic; Marcela Zivkovic; Iva Lucijanic; Zrinka Fabris; Rajko Kusec
Journal:  Int J Hematol       Date:  2017-10-11       Impact factor: 2.490

8.  Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival.

Authors:  S Rupoli; L Da Lio; S Sisti; G Campanati; A Salvi; M F Brianzoni; S D'Amico; A Cinciripini; P Leoni
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

9.  How I treat splenomegaly in myelofibrosis.

Authors:  F Cervantes
Journal:  Blood Cancer J       Date:  2011-10-07       Impact factor: 11.037

10.  Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Authors:  A Tefferi; O Abdel-Wahab; F Cervantes; J D Crispino; G Finazzi; F Girodon; H Gisslinger; J Gotlib; J-J Kiladjian; R L Levine; J D Licht; A Mullally; O Odenike; A Pardanani; R T Silver; E Solary; T Mughal
Journal:  Blood Cancer J       Date:  2011-03-04       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.